The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Biskup, Karina ^a   Braicu, Elena Iona ^a   Sehouli, Jalid ^a   Tauber, Rudolf ^a   Blanchard, Véronique ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; GLYCAN DERIVATIVE; GLYCOME; UNCLASSIFIED DRUG; POLYSACCHARIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN OVARY DISEASE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; EARLY CANCER; FEMALE; GLYCOME BLOOD LEVEL; GLYCOSYLATION; GLYCOV SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CARCINOMA; OVARY DISEASE; PREDICTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84907236103     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/238197     Document Type: Article

References (53)

1. Pinciroli P., Alberti C., Sensi M., Canevari S., Tomassetti A., An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response. BMC Genomics 2013 14, article 508 10.1186/1471-2164-14-508 2-s2.0-84880905633
2. Seidman J. D., Horkayne-Szakaly I., Haiba M., Boice C. R., Kurman R. J., Ronnett B. M., The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. International Journal of Gynecological Pathology 2004 23 1 41 44 10.1097/01.pgp.0000101080.35393.16 2-s2.0-0347511893
3. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA Cancer Journal for Clinicians 2012 62 1 10 29 10.3322/caac.20138 2-s2.0-84855792427
4. Lengyel E., Burdette J. E., Kenny H. A., Matei D., Pilrose J., Haluska P., Nephew K. P., Hales D. B., Stack M. S., Epithelial ovarian cancer experimental models. Oncogene 2014 33 3619 3633 10.1038/onc.2013.321 2-s2.0-84881164176
5. Fields M. M., Chevlen E., Ovarian cancer screening: a look at the evidence. Clinical Journal of Oncology Nursing 2006 10 1 77 81 10.1188/06.CJON.77-81 2-s2.0-33644973014
6. Greenlee R. T., Hill-Harmon M. B., Murray T., Thun M., Cancer Statistics, 2001. CA: A Cancer Journal for Clinicians 2001 51 1 15 36 10.3322/canjclin.51.1.15 2-s2.0-0035114558
7. Morice P., Brehier-Ollive D., Rey A., Atallah D., Lhommé C., Pautier P., Pomel C., Camatte S., Duvillard P., Castaigne D., Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Annals of Oncology 2003 14 1 74 77 10.1093/annonc/mdg003 2-s2.0-12244305147
8. Young R. C., Decker D. G., Wharton J. T., Piver M. S., Sindelar W. F., Edwards B. K., Smith J. P., Staging laparotomy in early ovarian cancer. Journal of the American Medical Association 1983 250 22 3072 3076 10.1001/jama.250.22.3072 2-s2.0-0021070283
9. Canney P. A., Moore M., Wilkinson P. M., James R. D., Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. British Journal of Cancer 1984 50 6 765 769 10.1038/bjc.1984.254 2-s2.0-0021702359
10. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C. Jr., CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstetrics & Gynecology 1987 69 2 223 227 2-s2.0-0023095431
11. van den Burg M. E. L., Lammes F. B., van Putten W. L. J., Stoter G., Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecologic Oncology 1988 30 3 307 312 10.1016/0090-8258(88)90244-2 2-s2.0-0023729656
12. Jacobs I., Bast R. C. Jr., The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction 1989 4 1 1 12 10.1093/humrep/4.suppl-1.1 2-s2.0-0024511529
13. Woolas R. P., Xu F., Jacobs I. J., Yu Y., Daly L., Berchuck A., Soper J. T., Clarke-Pearson D. L., Oram D. H., Bast R. C. Jr., Elevation of multiple serum markers in patients with stage I ovarian cancer. Journal of the National Cancer Institute 1993 85 21 1748 1751 10.1093/jnci/85.21.1748 2-s2.0-0027521696
14. Kaesemann H., Caffier H., Hoffmann F. J., Crombach G., Würz H., Kreienberg R., Möbus V., Schmidt-Rhode P., Sturm G., Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer: cancer antigen 125 as tumor marker: a cooperative study of the gynecological tumor marker group (GTMG). Klinische Wochenschrift 1986 64 17 781 785 10.1007/BF01732187 2-s2.0-0022772816
15. Klapdor R., Klapdor U., Bahlo M., Dallek M., Kremer B., van Ackeren H., Schreiber H. W., Greten H., CA 12-5 In carcinomas of the digestive tract: a comparison with CA 19-9 and CEA in carcinoma of the pancreas and colon. Deutsche Medizinische Wochenschrift 1984 109 51-52 1949 1954 10.1055/s-2008-1069483 2-s2.0-0021745324
16. Klug T. L., Bast R. C. Jr., Niloff J. M., Monoclonal antibodies immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Research 1984 44 3 1048 1053 2-s2.0-0021288888
17. Moore R. G., Bast R. C., How do you distinguish a malignant pelvic mass from a benign pelvic mass? imaging, biomarkers, or none of the above. Journal of Clinical Oncology 2007 25 27 4159 4161 10.1200/JCO.2007.11.9594 2-s2.0-34948853253
18. Heliström I., Raycraft J., Hayden-Ledbetter M., Ledbetter J. A., Schummer M., McIntosh M., Drescher C., Urban N., Hellström K. E., The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research 2003 63 13 3695 3700 2-s2.0-0038756386
19. Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C. Jr., Skates S. J., A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology 2009 112 1 40 46 10.1016/j.ygyno.2008.08.031 2-s2.0-57649088474
20. Moore R. G., Jabre-Raughley M., Brown A. K., Robison K. M., Miller M. C., Allard W. J., Kurman R. J., Bast R. C., Skates S. J., Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. The American Journal of Obstetrics and Gynecology 2010 203 3 228.e1 228.e6 10.1016/j.ajog.2010.03.043 2-s2.0-77956342398
21. Braicu E. I., Fotopoulou C., Van Gorp T., Richter R., Chekerov R., Hall C., Butz H., Castillo-Tong D. C., Mahner S., Zeillinger R., Concin N., Vergote I., Sehouli J., Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecologic Oncology 2013 128 2 245 251 10.1016/j.ygyno.2012.11.023 2-s2.0-84872870582
22. Taniguchi N., Ekuni A., Ko J. H., Miyoshi E., Ikeda Y., Ihara Y., Nishikawa A., Honke K., Takahashi M., A glycomic approach to the identification and characterization of glycoprotein function in cells transfected with glycosyltransferase genes. Proteomics 2001 1 2 239 247 10.1002/1615-9861(200102)1:2<239::AID-PROT239>3.0.CO;2-K 2-s2.0-0035260226
23. Helenius A., Aebi M., Roles of N-linked glycans in the endoplasmic reticulum. Annual Review of Biochemistry 2004 73 1019 1049 10.1146/annurev.biochem.73.011303.073752 2-s2.0-3943059566
24. Hakomori S., Glycosylation defining cancer malignancy: New wine in an old bottle. Proceedings of the National Academy of Sciences of the United States of America 2002 99 16 10231 10233 10.1073/pnas.172380699 2-s2.0-0036677372
25. Parekh R. B., Dwek R. A., Sutton B. J., Fernandes D. L., Leung A., Stanworth D., Rademacher T. W., Mizuochi T., Taniguchi T., Matsuta K., Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985 316 6027 452 457 10.1038/316452a0 2-s2.0-0022414766
26. van de Geijn F. E., Wuhrer M., Selman M. H. J., Willemsen S. P., de Man Y. A., Deelder A. M., Hazes J. M. W., Dolhain R. J. E. M., Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Research & Therapy 2009 11 6, article no. R193 10.1186/ar2892 2-s2.0-77952487132
27. Abd Hamid U. M., Royle L., Saldova R., Radcliffe C. M., Harvey D. J., Storr S. J., Pardo M., Antrobus R., Chapman C. J., Zitzmann N., Robertson J. F., Dwek R. A., Rudd P. M., A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008 18 12 1105 1118 10.1093/glycob/cwn095 2-s2.0-57049137606
28. Biskup K., Braicu E. I., Sehouli J., Fotopoulou C., Tauber R., Berger M., Blanchard V., Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. Journal of Proteome Research 2013 12 4056 4063 10.1021/pr400405x
29. Gornik O., Royle L., Harvey D. J., Radcliffe C. M., Saldova R., Dwek R. A., Rudd P., Lauc G., Changes of serum glycans during sepsis and acute pancreatitis. Glycobiology 2007 17 12 1321 1332 10.1093/glycob/cwm106 2-s2.0-36249003396
30. Mechref Y., Hussein A., Bekesova S., Pungpapong V., Zhang M., Dobrolecki L. E., Hickey R. J., Hammoud Z. T., Novotny M. V., Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. Journal of Proteome Research 2009 8 6 2656 2666 10.1021/pr8008385 2-s2.0-67149123659
31. Ozcan S., Barkauskas D. A., Renee Ruhaak L., Serum glycan signatures of gastric cancer. Cancer Prevention Research 2014 7 226 235 10.1158/1940-6207.CAPR-13-0235
32. Fotopoulou C., Richter R., Braicu E. I., Schmidt S.-C., Lichtenegger W., Sehouli J., Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. European Journal of Surgical Oncology 2010 36 12 1202 1210 10.1016/j.ejso.2010.09.008 2-s2.0-79952062502
33. Fotopoulou C., Schumacher G., Schefold J. C., Denkert C., Lichtenegger W., Sehouli J., Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary. International Journal of Gynecological Cancer 2009 19 9 1550 1555 10.1111/IGC.0b013e3181a84699 2-s2.0-77649216980
34. Sehouli J., Könsgen D., Mustea A., Oskay-Özcelik G., Katsares I., Weidemann H., Lichtenegger W., "IMO"-intraoperative mapping of ovarian cancer. Zentralblatt fur Gynakologie 2003 125 3-4 129 135 10.1055/s-2003-41864 2-s2.0-0042823451
35. Sehouli J., Richter R., Braicu E. I., Bühling K. J., Bahra M., Neuhaus P., Lichtenegger W., Fotopoulou C., Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. Journal of Surgical Oncology 2010 102 6 656 662 10.1002/jso.21652 2-s2.0-78349260017
36. Sehouli J., Savvatis K., Braicu E. I., Schmidt S. C., Lichtenegger W., Fotopoulou C., Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. International Journal of Gynecological Cancer 2010 20 8 1331 1340 2-s2.0-79952276947
37. Wedepohl S., Kaup M., Riese S. B., Berger M., Dernedde J., Tauber R., Blanchard V., N-glycan analysis of recombinant l-selectin reveals sulfated GalNAc and GalNAc-GalNAc motifs. Journal of Proteome Research 2010 9 7 3403 3411 10.1021/pr100170c 2-s2.0-77954357663
38. Alley W. R. Jr., Vasseur J. A., Goetz J. A., Svoboda M., Mann B. F., Matei D. E., Menning N., Hussein A., Mechref Y., Novotny M. V., N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. Journal of Proteome Research 2012 11 4 2282 2300 10.1021/pr201070k 2-s2.0-84859560597
39. Hua S., Williams C. C., Dimapasoc L. M., Ro G. S., Ozcan S., Miyamoto S., Lebrilla C. B., An H. J., Leiserowitz G. S., Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. Journal of Chromatography A 2013 1279 58 67 10.1016/j.chroma.2012.12.079 2-s2.0-84873283213
40. Saldova R., Royle L., Radcliffe C. M., Abd hamid U. M., Evans R., Arnold J. N., Banks R. E., Hutson R., Harvey D. J., Antrobus R., Petrescu S. M., Dwek R. A., Rudd P. M., Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007 17 12 1344 1356 10.1093/glycob/cwm100 2-s2.0-36248972262
41. de Leoz M. L. A., Young L. J. T., An H. J., Kronewitter S. R., Kim J., Miyamoto S., Borowsky A. D., Chew H. K., Lebrilla C. B., High-mannose glycans are elevated during breast cancer progression. Molecular and Cellular Proteomics 2011 10 1 10.1074/mcp.M110.002717-1 2-s2.0-78651063463
42. Hirani S., Lambris J. D., Muller-Eberhard H. J., Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochemical Journal 1986 233 2 613 616 2-s2.0-0022629028
43. Kyselova Z., Mechref Y., Al Bataineh M. M., Dobrolecki L. E., Hickey R. J., Vinson J., Sweeney C. J., Novotny M. V., Alterations in the serum glycome due to metastatic prostate cancer. Journal of Proteome Research 2007 6 5 1822 1832 10.1021/pr060664t 2-s2.0-34249277739
44. Arnold J. N., Saldova R., Galligan M. C., Murphy T. B., Mimura-Kimura Y., Telford J. E., Godwin A. K., Rudd P. M., Novel glycan biomarkers for the detection of lung cancer. Journal of Proteome Research 2011 10 4 1755 1764 10.1021/pr101034t 2-s2.0-79953704533
45. Brinkman-van der Linden E. C. M., de Haan P. F., Havenaar E. C., van Dijk W., Inflammation-induced expression of sialyl Lewis(x) is not restricted to 1-acid glycoprotein but also occurs to a lesser extent on 1- antichymotrypsin and haptoglobin. Glycoconjugate Journal 1998 15 2 177 182 10.1023/A:1006972307166 2-s2.0-0031809628
46. Turner G. A., Goodarzi M. T., Thompson S., Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Glycoconjugate Journal 1995 12 3 211 218 10.1007/BF00731322 2-s2.0-0029072297
47. Saitoh E., Aoki D., Susumu N., Udagawa Y., Nozawa S., Galactosyltransferase associated with tumor in patients with ovarian cancer: factors involved in elevation of serum galactosyltransferase. International Journal of Oncology 2003 23 2 303 310 2-s2.0-0344168395
48. Kuzmanov U., Musrap N., Kosanam H., Smith C. R., Batruch I., Dimitromanolakis A., Diamandis E. P., Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clinical Chemistry and Laboratory Medicine 2013 51 7 1467 1476 10.1515/cclm-2012-0642 2-s2.0-84883013056
49. Wang P., Lee W., Juang C., Yang Y., Lo W., Lai C., Hsieh S., Yuan C., Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecologic Oncology 2005 99 3 631 639 10.1016/j.ygyno.2005.07.016 2-s2.0-28044455199
50. Balkwill F., Mantovani A., Inflammation and cancer: back to Virchow? The Lancet 2001 357 9255 539 545 10.1016/S0140-6736(00)04046-0 2-s2.0-0035901090
51. Nilsson M. B., Langley R. R., Fidler I. J., Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Research 2005 65 23 10794 10800 10.1158/0008-5472.CAN-05-0623 2-s2.0-28244475975
52. Van Dijk W., Mackiewicz A., Interleukin-6-type cytokine-induced changes in acute phase protein glycosylation. Annals of the New York Academy of Sciences 1995 762 319 330 2-s2.0-0029111496
53. Bast R.C. Jr., Xu F. J., Yu Y. J., Barnhill S., Zhang Z., Mills G. B., CA 125: the past and the future. International Journal of Biological Markers 1998 13 4 179 187 2-s2.0-0032425863